Martinsried/Munich (pta031/12.11.2018/18:50) - Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced that it has entered into an exclusive license agreement with Leiden University Medical Center (LUMC), the Netherlands, for worldwide rights to develop, manufacture, and commercialize an HA-1-specific T cell receptor (TCR) as a targeted immunotherapy for cancer.
The TCR specific for the minor histocompatibility antigen HA-1 was developed by LUMC and tested for preliminary safety and tolerability in a Phase I clinical trial involving five patients. HA-1 is a well-characterized antigen expressed in cells of the hematopoietic system, in leukemia and lymphoma cells, as well as expressed in various solid tumors.
Medigene has licensed this HA-1-targeting T cell receptor to complement Medigene's preclinical and clinical development program. Its potential applicability in both liquid and solid tumors makes strategic sense within Medigene's growing internal pipeline.
Under the terms of the agreement, Medigene will receive the exclusive worldwide development and commercialization rights to the HA-1-specific TCR developed by LUMC. In return, LUMC will receive a one-time payment along with certain milestone payments. Upon commercialization, LUMC is eligible for royalties in the low-single digit percentage range. Confidentiality was agreed regarding further financial details.
Terms of the deal do not materially impact Medigene's financial guidance for the balance of the year 2018.
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Should you no longer wish to receive any information about Medigene, please inform us by e-mail (firstname.lastname@example.org). We will then delete your address.(end)
Lochhamer Straße 11
|contact person:||Julia Hofmann, Head of Public and Investor Relations|
|phone:||+49 89 200033-3301|
|stock exchanges:||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|